Treatment approaches for relapsed ovarian cancer have evolved over the past decade from a calendar-based decision tree to a patient-oriented biologically-driven algorithm. Nowadays, platinum-based chemotherapy should be offered to all patients with a reasonable chance of responding to this therapy. The treatment-free interval for platinum is only one of many factors affecting patients' eligibility for platinum re-treatment. Bevacizumab increases the response to chemotherapy irrespective of the cytotoxic regimen and can be valuable in patients with an urgent need for symptom relief (eg. pleural effusion, ascites). For patients with recurrent high grade ovarian cancer, which responds to platinum-based treatment maintenance therapy with a poly(ADP-ribose) polymerase (PARP) inhibitor can be offered, regardless of BRCA mutation status. Here we review contemporary decision-making processes in the systemic treatment of relapsed ovarian cancer.
T Baert, A Ferrero, J Sehouli, D M O Donnell, A González-Martín, F Joly, J van der Velden, P Blecharz, D S P Tan, D Querleu, N Colombo, A du Bois, J A Ledermann